Sarah V Colonna1, Ashantice K Higgins2, Joann Alvarez3, Benjamin R Saville3, Julia Lawrence2, Vandana G Abramson4. 1. Huntsman Cancer Institute, Salt Lake City, UT; George E. Whalen Veterans Affairs Hospital, Salt Lake City, UT; Vanderbilt-Ingram Cancer Center, Nashville, TN. Electronic address: sarah.colonna@hci.utah.edu. 2. Wake Forest Comprehensive Cancer Center, Winston-Salem, NC. 3. Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN. 4. Vanderbilt-Ingram Cancer Center, Nashville, TN.
Abstract
INTRODUCTION: Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with higher recurrence rates than other breast cancer subtypes. Increasing numbers of women are being diagnosed with early-stage breast cancer because of improvements in screening mammography. TNBC is known to be highly sensitive to chemotherapy; however, the benefit of adjuvant chemotherapy among women with ≤ 1-cm, lymph node-negative TNBC is unknown. MATERIALS AND METHODS: We evaluated the recurrence rates and recurrence-free survival of 437 women diagnosed with stage T1a-T1bN0 breast cancer from 1997 to 2009 at 2 institutions, with a median follow-up time of 6.2 years. Furthermore, we examined the treatment regimens of these women and evaluated the association of adjuvant chemotherapy with recurrence-free survival. RESULTS: Chemotherapy was administered more often to younger women and to women with high-grade, human epidermal growth factor receptor 2-positive or TNBC. Recurrence-free survival did not differ significantly between TNBC and estrogen receptor-positive breast cancer (hazard ratio [HR], 0.33; 95% confidence interval [CI], 0.10-1.04; P = .058). After appropriate adjustments, no significant differences were detected in recurrence-free survival between the women who had received chemotherapy and those who had not among the women with TNBC (P = .132) or within any of the breast cancer subtypes (HR, 0.6; 95% CI, 0.2-1.9; P = .392). CONCLUSION: Prospective trials of this subcentimeter node-negative breast cancer population are warranted to guide adjuvant chemotherapy decisions. Published by Elsevier Inc.
INTRODUCTION: Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with higher recurrence rates than other breast cancer subtypes. Increasing numbers of women are being diagnosed with early-stage breast cancer because of improvements in screening mammography. TNBC is known to be highly sensitive to chemotherapy; however, the benefit of adjuvant chemotherapy among women with ≤ 1-cm, lymph node-negative TNBC is unknown. MATERIALS AND METHODS: We evaluated the recurrence rates and recurrence-free survival of 437 women diagnosed with stage T1a-T1bN0 breast cancer from 1997 to 2009 at 2 institutions, with a median follow-up time of 6.2 years. Furthermore, we examined the treatment regimens of these women and evaluated the association of adjuvant chemotherapy with recurrence-free survival. RESULTS: Chemotherapy was administered more often to younger women and to women with high-grade, humanepidermal growth factor receptor 2-positive or TNBC. Recurrence-free survival did not differ significantly between TNBC and estrogen receptor-positive breast cancer (hazard ratio [HR], 0.33; 95% confidence interval [CI], 0.10-1.04; P = .058). After appropriate adjustments, no significant differences were detected in recurrence-free survival between the women who had received chemotherapy and those who had not among the women with TNBC (P = .132) or within any of the breast cancer subtypes (HR, 0.6; 95% CI, 0.2-1.9; P = .392). CONCLUSION: Prospective trials of this subcentimeter node-negative breast cancer population are warranted to guide adjuvant chemotherapy decisions. Published by Elsevier Inc.
Entities:
Keywords:
Chemotherapy; HER2(+); Node negative; Small tumor; Triple negative
Authors: Genevieve A Fasano; Solange Bayard; Yalei Chen; Leticia Varella; Tessa Cigler; Jessica Bensenhaver; Rache Simmons; Alexander Swistel; Jennifer Marti; Anne Moore; Eleni Andreopoulou; John Ng; Andrew Brandmaier; Silvia Formenti; Haythem Ali; Melissa Davis; Lisa Newman Journal: Breast Cancer Res Treat Date: 2022-01-13 Impact factor: 4.872